Vorapaxar is the company’s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. “There are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have…